Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: Application to an HIV program in Mozambique

American Journal of Epidemiology

Volumn 178, Issue 5, 2013, Pages 819-828

  Shepherd, Bryan E ^a   Blevins, Meridith ^a   Vaz, Lara M E ^a,b   Moon, Troy D ^a,b   Kipp, Aaron M ^a   José, Eurico ^b   Ferreira, Ferreira G ^b   Vermund, Sten H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Friends in Global Health   (Mozambique)

Author keywords

chronic disease; cohort studies; HIV; long term care; lost to follow up; program evaluation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CHRONIC WASTING DISEASE; COHORT ANALYSIS; DISEASE; HEALTH CARE; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DEATH; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LOSS TO FOLLOW UP; MAJOR CLINICAL STUDY; MEDICAL TERMINOLOGY; MORTALITY; MOZAMBIQUE; PRACTICE GUIDELINE;

CHRONIC DISEASE; COHORT STUDIES; HIV; LONG-TERM CARE; LOST TO FOLLOW-UP; PROGRAM EVALUATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MOZAMBIQUE; PATIENT ACCEPTANCE OF HEALTH CARE; RESEARCH DESIGN; TIME FACTORS;

MOZAMBIQUE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84883134112     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt030     Document Type: Article

References (53)

1. Department of Chronic Diseases and Health Promotion. Preventing Chronic Diseases: AVital Investment. Geneva, Switzerland:World Health Organization; 2005
2. Beaglehole R, Epping-Jordan J, Patel V, et al. Improving the prevention and management of chronic disease in low-income and middle-income countries: A priority for primary health care. Lancet. 2008;372(9642):940-949
3. Harries AD, Zachariah R, Kapur A, et al. The vital signs of chronic disease management. Trans R Soc Trop Med Hyg. 2009;103(6):537-540
4. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis. 2010; 51(6):725-731
5. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531-536
6. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: A systematic review. PLoS Med. 2007;4(10):e298
7. BrinkhofMW, Dabis F, Myer L, et al. Early loss of HIVinfected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008; 86(7):559-567
8. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir ImmuneDefic Syndr. 2009;51(5):615-623
9. Tassie JM, Baijal P, Vitoria MA, et al. Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr. 2010;54(4):437-441
10. Shepherd BE, Sterling TR, Moore RD, et al. Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. J Clin Epidemiol. 2009;62(7):729-737
11. Giordano TP, Gifford AL, White AC Jr, et al. Retention in care: A challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493-1499
12. Gerver SM, Chadborn TR, Ibrahim F, et al. High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: A retrospective analysis of a clinical cohort. J Int AIDS Soc. 2010;13(1
13. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet. 2006;367(9513):817-824
14. Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: A statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011;9(10):e1001111
15. Mugavero MJ, Davila JA, Nevin CR, et al. From access to engagement: Measuring retention in outpatient HIV clinical care. AIDS Patient Care STDS. 2010;24(10):607-613
16. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: Implications for global scale-up efforts. PLoS One. 2008;3(3):e1725
17. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA. 2006;296(7):782-793
18. McGuire M, Munyenyembe T, Szumilin E, et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health. 2010;15(suppl 1):55-62
19. Hosseinipour MC, Neuhann FH, Kanyama CC, et al. Lessons learned from a paying antiretroviral therapy service in the public health sector at Kamuzu Central Hospital, Malawi: 1-year experience. J Int Assoc Physicians AIDS Care (Chic). 2006;5(3):103-108
20. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40(3):336-343
21. Yu JK, Chen SC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ. 2007;85(7):550-554
22. Chi BH, Cantrell RA, Mwango A, et al. An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol. 2010;171(8):924-931
23. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district ofMalawi: An effectiveness assessment. Lancet. 2006;367(9519):1335-1342
24. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: Experience from western Kenya. AIDS. 2006;20(1):41-48
25. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS. 2003;17(suppl 3):S5-S15
26. Laurent C, Meilo H, Guiard-Schmid JB, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: Lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis. 2005;41(1):108-111
27. Zachariah R, Teck R, Buhendwa L, et al. Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Trans R Soc Trop Med Hyg. 2007;101(1):79-84
28. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18(6):887-895
29. Sow PS, Otieno LF, Bissagnene E, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: Clinical results from 4 African countries. J Acquir Immune Defic Syndr. 2007;44(3):262-267
30. Krishnan S, Wu K, Smurzynski M, et al. Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-Treated HIV-infected persons: An AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV Clin Trials. 2011;12(4):190-200
31. Cuong DD, Thorson A, Sonnerborg A, et al. Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam. Scand J Infect Dis. 2012;44(3):201-208
32. Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008;13(8):1005-1015
33. Lurton G, Akonde A, Madec Y, et al. Looking for lost to follow-up patients: Experience of Segou, Mali [abstract]. Presented at the International AIDS Conference, Mexico City, Mexico, August 3-8, 2008
34. Joshi K, Jhanwar S, Mathur A, et al. Barriers in adherence of ART (anti retroviral treatment): A experience of ART Centre ofWestern Rajasthan, India [abstract]. Presented at the International AIDS Conference, Mexico City, Mexico, August 3-8, 2008
35. Muwanga A, Easterbrook P, Schaefer P, et al. Losses to follow-up in a large ART program in Uganda [abstract]. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 3-6, 2008
36. Karcher H, Omondi A, Odera J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007; 12(5):687-694
37. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a samplingbased approach. J Acquir Immune Defic Syndr. 2010; 53(3):405-411
38. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: A 7-year cohort study. AIDS. 2006; 20(8):1181-1189
39. Ndiaye B, Ould-Kaci K, Salleron J, et al. Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up. AIDS. 2009;23(13):1786-1789
40. Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009;199(7): 991-998
41. Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis. 2007; 195(3):425-431
42. Egger M, Spycher BD, Sidle J, et al. Correcting mortality for loss to follow-up: A nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med. 2011;8(1):e1000390
43. Schoni-Affolter F, Keiser O, Mwango A, et al. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: The effect of the competing risk of death in Zambia and Switzerland. PLoS One. 2011;6(12):e27919
44. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4(+) counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr. 2007;44(2):179-187
45. Moon TD, Burlison JR, Blevins M, et al. Enrolment and programmatic trends and predictors of antiretroviral therapy initiation from President's Emergency Plan for AIDS Relief (PEPFAR)-supported public HIV care and treatment sites in rural Mozambique. Int J STD AIDS. 2011;22(11): 621-627
46. World Health Organization. Monitoring services, patients and programmes. In: Operations Manual for Delivery of HIV Prevention, Care and Treatment at Primary Health Centres in High-Prevalence, Resource-constrained Settings. Edition 1 for field testing and country adaptation. Geneva, Switzerland: World Health Organization; 2008:120
47. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY:Wiley; 1980
48. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: Systematic review and meta-Analysis. PLoS One. 2009;4(6): E5790
49. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779-788
50. Hogan JW, Laird NM. Model-based approaches to analysing incomplete longitudinal and failure time data. Stat Med. 1997;16(1-3):259-272
51. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: Evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010;15(4): 405-413
52. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300(5):506-507
53. Yiannoutsos CT, An MW, Frangakis CE, et al. Sampling-based approaches to improve estimation of mortality among patient dropouts: Experience from a large PEPFAR-funded program in western Kenya. PLoS One. 2008;3(12):e3843